Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 août 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
01 août 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million ...
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
25 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
24 juil. 2024 08h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
17 juil. 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 juin 2024 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2024 20h49 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
12 juin 2024 16h05 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
12 juin 2024 16h00 HE
|
Ultragenyx Pharmaceutical Inc.
Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear...